| (Values in U.S. Thousands) | Sep, 2017 | Jun, 2017 | Mar, 2017 | Dec, 2016 | Sep, 2016 |
| Sales | -9,999,000 | 44,520 | 42,890 | 44,060 | 40,540 |
| Sales Growth | -22,559.57% | +3.80% | -2.66% | +8.68% | +3.98% |
| Net Income | -9,999,000 | 12,190 | 14,600 | 6,410 | 10,120 |
| Net Income Growth | -82,126.25% | -16.51% | +127.77% | -36.66% | +59.62% |
Sciclone Pharmaceut (SCLN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Sciclone Pharmaceuticals, Inc. develops and commercializes novel medicines for treating a broad range of the world's most serious diseases. They have focused their current product development and commercial activities on the following diseases: hepatitis C, hepatocellular carcinoma, malignant melanoma, hepatitis B, HIV, drug-resistant tuberculosis, cystic fibrosis and others.
Fiscal Year End Date: 12/31